Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Total Non-Current Liabilities (2016 - 2022)

Historic Total Non-Current Liabilities for Cardiff Oncology (CRDF) over the last 13 years, with Q4 2022 value amounting to $9.8 million.

  • Cardiff Oncology's Total Non-Current Liabilities rose 789.96% to $9.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was $9.8 million, marking a year-over-year increase of 789.96%. This contributed to the annual value of $9.8 million for FY2022, which is 789.96% up from last year.
  • Per Cardiff Oncology's latest filing, its Total Non-Current Liabilities stood at $9.8 million for Q4 2022, which was up 789.96% from $9.1 million recorded in Q4 2021.
  • Over the past 5 years, Cardiff Oncology's Total Non-Current Liabilities peaked at $9.8 million during Q4 2022, and registered a low of $3.9 million during Q3 2018.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $5.3 million (2019), whereas its average is $5.7 million.
  • In the last 5 years, Cardiff Oncology's Total Non-Current Liabilities crashed by 7844.41% in 2018 and then surged by 4524.19% in 2021.
  • Over the past 5 years, Cardiff Oncology's Total Non-Current Liabilities (Quarter) stood at $4.0 million in 2018, then soared by 39.56% to $5.6 million in 2019, then increased by 11.28% to $6.3 million in 2020, then skyrocketed by 45.24% to $9.1 million in 2021, then grew by 7.9% to $9.8 million in 2022.
  • Its Total Non-Current Liabilities stands at $9.8 million for Q4 2022, versus $9.1 million for Q4 2021 and $7.7 million for Q3 2021.